Story perspectives

Breakthrough RAD51 Assay Promises New Hope for Prostate Cancer

2/9/2025

36 5

Summary

Story summary

Researchers at Vall d'Hebron Institute of Oncology have made a breakthrough with a RAD51 assay that could revolutionize cancer treatment. By examining 219 biopsies from advanced prostate cancer patients, they discovered that 21% had low RAD51 scores, signaling a deficiency in DNA repair. Remarkably, these patients experienced longer progression-free survival when treated with PARP inhibitors, highlighting RAD51's potential to enhance patient care alongside existing methods.

1 of 1

Story summary

Researchers at Vall d'Hebron Institute of Oncology have made a breakthrough with a RAD51 assay that could revolutionize cancer treatment. By examining 219 biopsies from advanced prostate cancer patients, they discovered that 21% had low RAD51 scores, signaling a deficiency in DNA repair. Remarkably, these patients experienced longer progression-free survival when treated with PARP inhibitors, highlighting RAD51's potential to enhance patient care alongside existing methods.